Table 1 Current clinical trials of EPZ-5676
From: Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
ClinicalTrials.gov identifier | Study title | Status |
|---|---|---|
NCT01684150 | A phase 1, open-label, dose-escalation and expanded cohort, continuous IV infusion, multi-center study of the safety, tolerability, PK and PD of EPZ-5676 in treatment relapsed/refractory patients with leukemias involving | Completed |
NCT02141828 | A phase 1 dose escalation and expanded cohort Study of EPZ-5676 in the treatment of pediatric patients with relapsed/Refractory leukemias bearing a rearrangement of the MLL gene | Completed |
NCT03701295 | Pinometostat and azacitidine in treating patients with relapsed, refractory, or newly diagnosed acute myeloid leukemia with 11q23 rearrangement | Completed Has Results |
NCT03724084 | Pinometostat with standard chemotherapy in treating patients with newly diagnosed acute myeloid leukemia and MLL gene rearrangement | Active, not recruiting |